scholarly journals Trajectories of Cognitive Function Prior to Cancer Diagnosis: A Population-Based Study

2019 ◽  
Vol 112 (5) ◽  
pp. 480-488 ◽  
Author(s):  
Kimberly D van der Willik ◽  
Michael Hauptmann ◽  
Katarzyna Jóźwiak ◽  
Elisabeth J Vinke ◽  
Rikje Ruiter ◽  
...  
Keyword(s):  
Nervous System ◽  
Cognitive Function ◽  
Confidence Interval ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Sensitivity Analyses ◽  
Cognitive Tests ◽  
Control Subjects ◽  
Nervous System Cancer

Abstract Background An emerging body of research suggests that noncentral nervous system cancer may negatively impact the brain apart from effects of cancer treatment. However, studies assessing cognitive function in newly diagnosed cancer patients cannot exclude selection bias and psychological effects of cancer diagnosis. To overcome these limitations, we investigated trajectories of cognitive function of patients before cancer diagnosis. Methods Between 1989 and 2013, a total of 2059 participants from the population-based Rotterdam Study were diagnosed with noncentral nervous system cancer. Cognitive assessments were performed every 3 to 5 years using a neuropsychological battery. The general cognitive factor was composed of individual cognitive tests to assess global cognition. Using linear mixed models, we compared change in cognitive function of cancer case patients before diagnosis with cognitive change of age-matched cancer-free control subjects (1:2). In addition, we performed sensitivity analyses by discarding assessments of control subjects 5 years before the end of follow-up to exclude effects from potential undiagnosed cancer. All statistical tests were two-sided. Results The Word Learning Test immediate recall declined faster among case patients than among control subjects (−0.05, 95% confidence interval = −0.09 to −0.01 vs 0.01, 95% confidence interval = −0.01 to 0.03; P for difference = .003). However, this difference was not statistically significant in sensitivity analyses. Furthermore, no statistically significant differences were observed in change of other individual cognitive tests and of the general cognitive factor. Conclusions In this study, we evaluated cognitive function in a large group of cancer patients prior to diagnosis, thereby excluding the psychological impact of cancer diagnosis and biased patient selection. In contrast to previous studies shortly after cancer diagnosis, we found no difference in change of cognitive function between cancer patients and control subjects.

Change in cognition before and after non‐central nervous system cancer diagnosis: a population‐based cohort study

2021 ◽  
Author(s):  
Kimberly D. van der Willik ◽  
Katarzyna Jóźwiak ◽  
Michael Hauptmann ◽  
Edolie E.D. van de Velde ◽  
Annette Compter ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Central Nervous System Cancer ◽  
Before And After ◽  
Nervous System Cancer

scholarly journals Brain structure prior to non-central nervous system cancer diagnosis: A population-based cohort study

2020 ◽  
Vol 28 ◽  
pp. 102466
Author(s):  
Kimberly D. van der Willik ◽  
Pinar Yilmaz ◽  
Annette Compter ◽  
Michael Hauptmann ◽  
Katarzyna Jóźwiak ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Brain Structure ◽  
Population Based ◽  
Central Nervous System Cancer ◽  
Nervous System Cancer

Syncope in migraine

Neurology ◽  
2006 ◽  
Vol 66 (7) ◽  
pp. 1034-1037 ◽  
Author(s):  
R. D. Thijs ◽  
M. C. Kruit ◽  
M. A. van Buchem ◽  
M. D. Ferrari ◽  
L. J. Launer ◽  
...  
Keyword(s):  
Nervous System ◽  
Autonomic Nervous System ◽  
Orthostatic Intolerance ◽  
Population Based ◽  
Lifetime Prevalence ◽  
Postural Tachycardia Syndrome ◽  
Population Based Study ◽  
Autonomic Nervous ◽  
Control Subjects ◽  
And Control

Objective: To examine the association between migraine and syncope-related autonomic nervous system (ANS) symptoms.Methods: A population-based study among migraineurs with and without aura (n = 323) and control subjects (n = 153) was conducted. A systematic questionnaire and cardiovascular measurements during rest, while standing, and after venipuncture addressed the prevalence of syncope, orthostatic intolerance, orthostatic hypotension (OH), and the postural tachycardia syndrome (POTS) in migraineurs and control subjects.Results: The lifetime prevalence of syncope in all participants was 41%, more often in women (45 vs 32%; p = 0.02). Compared with control subjects, migraineurs had a higher lifetime prevalence of syncope (46 vs 31%; p = 0.001), frequent syncope (five or more attacks) (13 vs 5%; p = 0.02), and orthostatic intolerance (32 vs 12%; p < 0.001). There was no association between ANS symptoms and the severity of migraine or migraine subtype. Cardiovascular measurements and the prevalence of POTS and OH did not differ significantly between migraineurs and control subjects.Conclusion: This population-based study demonstrated an elevated prevalence of syncope and orthostatic intolerance in migraineurs without clear interictal signs of autonomic nervous system dysfunction.

Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9570-9570
Author(s):  
C. F. Christiansen ◽  
M. B. Johansen ◽  
S. Christensen ◽  
W. Langeberg ◽  
J. P. Fryzek ◽  
...  
Keyword(s):  
At Risk ◽  
Multiple Myeloma ◽  
Acute Kidney Injury ◽  
Cohort Study ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Kidney Injury ◽  
Population Based ◽  
First Year ◽  
Increased Risk

9570 Background: Although cancer patients may be at increased risk for acute kidney injury (AKI), which could then reduce their likelihood of receiving optimal therapeutic management and supportive care, the occurrence of AKI among newly diagnosed cancer patients has not been well-described. Therefore, we examined the incidence of AKI within the first year after cancer diagnosis to estimate the magnitude of this risk and better understand which patients are at greatest risk. Methods: Using the population-based Danish Cancer Registry, we conducted a retrospective cohort study of 4,427 men and women from North Jutland, Denmark (population 500,000) diagnosed with cancer from 2002 to 2003 (non-melanoma skin cancer excluded). AKI was defined according to the Risk/ Injury/ Failure/ Loss/ End-stage-renal-disease (RIFLE) criteria. We included Risk or worse: at least a 1.5 times increase in serum creatinine (sCr) from baseline. SCr levels were obtained from the Regional Laboratory Database, which collects all biochemical analyses for hospital laboratories. Baseline sCr was defined as the lowest sCr in the year before cancer diagnosis. We compared this value to the highest sCr on record during the first year following cancer diagnosis to identify those who experienced an AKI. Results: Median age for the cohort was 68.6 years, 50.9% were men, and the most common cancer sites were lung (14.2%), breast (13.7%), prostate (9.8%), colon (9.6%), rectum (5.1%), and bladder (6.3%). During the first year, 973 (22.0%) members of the cohort experienced an AKI, corresponding to an overall incidence rate of 326 per 1,000 person-years (95% confidence interval (CI) 306–347). Incidence was highest among patients aged 80 years or older (531 per 1,000 person-years, 95% CI 464–606) and in those with cancer of the liver (1,221, 95%CI 676–2,205), pancreas (1,472, 95%CI 1,130–1,917), or kidney (1,254, 95%CI 974–1,616), or with multiple myeloma (855, 95%CI 538–1,356). Conclusions: To protect against AKI, we must first identify those at risk. Our study showed that over 20% of cancer patients may experience acute kidney injury in the first year after diagnosis. Older patients and those with cancer of the liver, pancreas, or kidney, or with multiple myeloma are especially at risk for AKI. [Table: see text]

Genetic Predisposition to Cervical Cancer and the Association With XRCC1 and TGFB1 Polymorphisms

2017 ◽  
Vol 27 (9) ◽  
pp. 1949-1956 ◽  
Author(s):  
Najla M. Al-Harbi ◽  
Sara S. Bin Judia ◽  
Krishna N. Mishra ◽  
Mohamed M. Shoukri ◽  
Ghazi A. Alsbeih
Keyword(s):  
Confidence Interval ◽  
Cancer Patients ◽  
Genetic Predisposition ◽  
Odds Ratio ◽  
Direct Sequencing ◽  
Trend Test ◽  
Nucleotide Polymorphisms ◽  
Control Subjects ◽  
Allele Dosage ◽  
Increased Risk

ObjectiveCervical carcinoma (CC), a multifactorial cancer, is assumed to have a host genetic predisposition component that modulates its susceptibility in various populations. We investigated the association between CC risk in Saudi women and 6 single-nucleotide polymorphisms (SNPs) in hypothesis-driven candidate genes.MethodsA total of 545 females were included, comprising 232 CC patients and 313 age-/sex-matched control subjects. Six SNPs (CDKN1A C31A, ATM G1853A, HDM2 T309G, TGFB1 T10C, XRCC1 G399A, and XRCC3 C241T) were genotyped by direct sequencing.ResultsOf the 6 SNPs studied, TGFB1 T10C (odds ratio, 0.74; 95% confidence interval, 0.57–0.94) and XRCC1 G399A (odds ratio, 1.45; 95% confidence interval, 1.11–1.90) displayed different frequencies in cancer patients and control subjects and showed statistically significant association in univariate (P = 0.017, P = 0.005, respectively) analysis. The Cochran-Armitage trend test had confirmed the results (P = 0.027 and P = 0.006, respectively), indicating an ordering in the effect of the risk alleles in CC patients. The 2 SNPs, TGFB1 T10C and XRCC1 G399A, showed also degrees of deviation from Hardy-Weinberg equilibrium in cancer patients (P = 0.001 and P = 0.083, respectively) but not in the control subjects. Furthermore, correction for multiple testing using multivariate logistic regression to assess the joint effect of all SNPs has sustained significant statistical association (P = 0.025 and P = 0.009, respectively).ConclusionsTGFB1 T10C and XRCC1 G399A SNPs were associated with CC risk in univariate and multivariate analysis and displayed allele-dosage effects and coselection in cancer patients. Patients harboring the majority allele TGFB1 T10 (Leu) or the variant allele XRCC1 399A (Gln) have approximately 1.5-fold increased risk to develop CC. Host SNPs genotyping may provide relevant biomarkers for CC risk assessment in personalized preventive medicine.

scholarly journals Risk of Suicide After a Cancer Diagnosis in England: A Population-Based Study

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 228s-228s
Author(s):  
K. Henson ◽  
R. Brock ◽  
J. Charnock ◽  
B. Wickramasinghe ◽  
O. Will ◽  
...  
Keyword(s):  
At Risk ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Suicide Risk ◽  
Population Level ◽  
Population Based ◽  
Psychological Support ◽  
Cancer Type ◽  
Increased Risk ◽  
Icd 10

Background: Previous research has identified an increased risk of suicide among cancer patients, however this has not been investigated at a population level in England. Those subgroups of patients most at risk need to be identified to ensure appropriate access to psychological support. Aim: To examine the variation in suicide risk among individuals diagnosed with cancer in England. Methods: We identified 4,453,547 individuals (21 million person-years at risk) aged 18 to 99 years at diagnosis of cancer during 1995 to 2015 from the national cancer registry, and followed them up until 31 August 2017. The outcomes of interest were both suicide and open verdicts (ICD-10 X60-X84, Y87.0, Y10-Y34 [excluding Y33.9, Y87.2]). Population-based expected deaths were as published by ONS [2]. We calculated standardized mortality ratios (SMRs) and absolute excess risks (AERs), and explored variation in suicide risk by cancer type, age at death, sex, deprivation, ethnicity, and years since cancer diagnosis. Results: 2352 cancer patients died by suicide. This was 0.08% of all deaths. The overall SMR for suicide was 1.19 (95% CI 1.14-1.24) and AER per 10,000 person-years was 0.18 (0.13-0.22). The risk was highest among individuals diagnosed with mesothelioma, with a 4.34-fold risk corresponding to 4.00 extra deaths per 10,000 person-years. This was followed by pancreatic (3.94-fold), esophageal (2.53-fold), lung (2.52-fold), and stomach (2.14-fold) cancer (all significantly elevated). Suicide risk was highest in the first 6 months following cancer diagnosis (SMR: 2.64 [2.42-2.89]), but a significantly increased risk persisted for 2 years (SMR: 1.21 [1.08-1.35]). Conclusion: Despite low numbers, the elevated risk of suicide in patients with certain cancers is a concern, representing potentially preventable deaths. The increased risk in the first 6 months after diagnosis, which is consistent with previous studies, highlights unmet needs for psychological support delivered alongside cancer diagnosis and treatment. Our findings suggest a need for improved risk stratification across cancer services, followed by targeted psychological support.

scholarly journals Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Shinechimeg Dima ◽  
Kun-Huang Chen ◽  
Kung-Jeng Wang ◽  
Kung-Min Wang ◽  
Nai-Chia Teng
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Physician Visits ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Kaplan Meier ◽  
Diagnosis Of Lung Cancer

The effect of comorbidity on lung cancer patients’ survival has been widely reported. The aim of this study was to investigate the effects of comorbidity on the establishment of the diagnosis of lung cancer and survival in lung cancer patients in Taiwan by using a nationwide population-based study design. This study collected various comorbidity patients and analyzed data regarding the lung cancer diagnosis and survival during a 16-year follow-up period (1995–2010). In total, 101,776 lung cancer patients were included, comprising 44,770 with and 57,006 without comorbidity. The Kaplan–Meier analyses were used to compare overall survival between lung cancer patients with and without comorbidity. In our cohort, chronic bronchitis patients who developed lung cancer had the lowest overall survival in one (45%), five (28.6%), and ten years (26.2%) since lung cancer diagnosis. Among lung cancer patients with nonpulmonary comorbidities, patients with hypertension had the lowest overall survival in one (47.9%), five (30.5%), and ten (28.2%) years since lung cancer diagnosis. In 2010, patients with and without comorbidity had 14.86 and 9.31 clinical visits, respectively. Lung cancer patients with preexisting comorbidity had higher frequency of physician visits. The presence of comorbid conditions was associated with early diagnosis of lung cancer.

scholarly journals Arterial thromboembolic events preceding the diagnosis of cancer in older persons

Blood ◽  
2019 ◽  
Vol 133 (8) ◽  
pp. 781-789 ◽  
Author(s):  
Babak B. Navi ◽  
Anne S. Reiner ◽  
Hooman Kamel ◽  
Costantino Iadecola ◽  
Peter M. Okin ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Older Persons ◽  
Population Based ◽  
Primary Diagnosis ◽  
Thromboembolic Events ◽  
Arterial Thromboembolism ◽  
Non Hodgkin Lymphoma ◽  
Increased Risk ◽  
Arterial Thromboembolic Events

Abstract Cancer patients face an increased risk of arterial thromboembolism; however, it is uncertain when this excess risk begins. This study evaluated the risk of arterial thromboembolism before cancer diagnosis. Using the population-based Surveillance Epidemiology and End Results-Medicare linked dataset, we identified 374 331 patients ≥67 years of age with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, uterine, pancreatic, gastric cancer, or non-Hodgkin lymphoma from 2005 through 2013. Cancer patients were individually matched by demographics and comorbidities to Medicare beneficiaries without cancer, who served as controls. Validated diagnosis codes were used to identify arterial thromboembolic events, defined as a composite of myocardial infarction or ischemic stroke. The Mantel-Haenszel estimator was used to compare risks of arterial thromboembolic events between cancer and noncancer groups during 30-day periods in the 360 days before date of cancer diagnosis. From 360 to 151 days before cancer diagnosis, the 30-day interval risks of arterial thromboembolic events were similar between cancer patients and matched controls. From 150 to 1 day before cancer diagnosis, the interval 30-day risks of arterial thromboembolic events were higher in cancer patients vs matched controls, progressively increasing as the cancer diagnosis date approached and peaking during the 30 days immediately before cancer diagnosis, when 2313 (0.62%) cancer patients were diagnosed with an arterial thromboembolic event vs 413 (0.11%) controls (odds ratio, 5.63; 95% confidence interval, 5.07-6.25). In conclusion, the risk of arterial thromboembolic events begins to increase 150 days before the date of cancer diagnosis in older persons and peaks in the 30 days before.

Sign in / Sign up

Export Citation Format

Share Document